Sellas Life Sciences is trading 10.8% up today at $11.09, extending its recent rebound after last week’s pullback.
- Bullish sentiment is being driven by optimism surrounding the company's late-stage REGAL trial.
- Reports of strong institutional interest in the stock are fueling the upward momentum.
- A broader risk-on rally in U.S. equities is providing an additional tailwind for the biotech sector.